TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31442616

Group type: EXPERIMENTAL
Intervention: Discogenic cells injected intradiscally in a rabbit model of DD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discogenic cells injected subcutaneously in nude mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control discs or injection of vehicle alone (no cells)
Number of subjects: 0
Study: 31442817

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg IV every 3 weeks) + Metronomic cyclophosphamide (50 mg b.i.d. one week on and one week off)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 31443253

Group type: EXPERIMENTAL
Intervention: HIV-1 transmitted/founder (T/F) viruses in the CNS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-genome sequencing of envelope gene
Number of subjects: 0
Study: 31443343

Group type: EXPERIMENTAL
Intervention: Medical supervision with dietary recommendations
Number of subjects: 0
Study: 31443741

Group type: EXPERIMENTAL
Intervention: Samalizumab (50 to 600 mg/m)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Samalizumab
Number of subjects: 26
Study: 31443976

Group type: EXPERIMENTAL
Intervention: Isolated type II endoleak
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Type II endoleak
Number of subjects: 197

Group type: COMPARATOR
Intervention: Early type II endoleak
Number of subjects: 197
Study: 31444088

Group type: EXPERIMENTAL
Intervention: Modified Geriatric Assessment (mGA) including Geriatric Depression Scale-15 (GDS) and Timed Up and Go (TUG)
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Growth mixture model for PF trajectories
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Pre-treatment pain and dyspnea
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Depressive symptoms, reduced mobility, and more physical symptoms
Number of subjects: 307
Study: 31444186

Group type: EXPERIMENTAL
Intervention: Care in a neonatal intensive care unit (NICU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care in a local neonatal unit (LNU)
Number of subjects: 0
Study: 31444190

Group type: EXPERIMENTAL
Intervention: Intraoperative monitoring of haemodynamic measurements such as the Toe-Brachial Index during endovascular surgery.
Number of subjects: 80
Study: 31444250

Group type: EXPERIMENTAL
Intervention: Anti-CD19 JWCAR029 CAR T cells
Number of subjects: 10
Study: 31444600

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate
Number of subjects: 586
Study: 31444849

Group type: EXPERIMENTAL
Intervention: SSM@100Hz
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Baveno VI criteria + SSM@100Hz
Number of subjects: 260

Group type: COMPARATOR
Intervention: Baveno VI criteria + SSM@50Hz
Number of subjects: 260

Group type: COMPARATOR
Intervention: Baveno VI criteria alone
Number of subjects: 260
Study: 31445199

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg every 2 weeks for up to 2 years
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 1008
Study: 31446142

Group type: EXPERIMENTAL
Intervention: Self-administered electronic screening for SUD risk, depression and anxiety using TAPS and AOQ measures
Number of subjects: 5000

Group type: COMPARATOR
Intervention: Usual care (24-month period prior to intervention)
Number of subjects: 5000
Study: 31446511

Group type: EXPERIMENTAL
Intervention: Apalutamide 240 mg once-daily for 1 week, followed by continuous daily dosing (4 weeks/cycle)
Number of subjects: 6
Study: 31446987

Group type: EXPERIMENTAL
Intervention: Rovalpituzumab tesirine (Rova-T) 0.2 or 0.3 mg/kg by intravenous infusion on Day 1 of each 6-week cycle for 2 doses and dexamethasone (8 mg BID oral) on D-1, D1, and D2 of each 6-week cycle
Number of subjects: 29
Study: 31447247

Group type: EXPERIMENTAL
Intervention: Nutrition care quality indicators (QIs)
Number of subjects: 46
Study: 31447780

Group type: EXPERIMENTAL
Intervention: A1C test
Number of subjects: 0
Study: 31448107

Group type: EXPERIMENTAL
Intervention: Home-based exercise program after total hip arthroplasty, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise program after total hip arthroplasty, details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details not available.
Number of subjects: 0
Study: 31448214

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT) with a prescription dose of 68.1 Gy in 30 fractions
Number of subjects: 35
Study: 31448496

Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Creatinine
Number of subjects: 173
Study: 31449299

Group type: EXPERIMENTAL
Intervention: More aggressive organ acceptance practices
Number of subjects: 156089

Group type: EXPERIMENTAL
Intervention: Redesigned system with more aggressive organ acceptance practices
Number of subjects: 156089

Group type: COMPARATOR
Intervention: Kidney transplant in the United States
Number of subjects: 156089

Group type: COMPARATOR
Intervention: Kidney transplant in France
Number of subjects: 156089

Group type: COMPARATOR
Intervention: Kidney quality over time in the United States
Number of subjects: 156089

Group type: COMPARATOR
Intervention: Kidney quality over time in France
Number of subjects: 156089
Study: 31449468

Group type: EXPERIMENTAL
Intervention: Regimen DD4A (vincristine, dactinomycin, and doxorubicin) for stage I/II disease
Number of subjects: 2511

Group type: EXPERIMENTAL
Intervention: Regimen M (vincristine, dactinomycin, doxorubicin alternating with cyclophosphamide and etoposide) and radiation therapy for stage III/IV disease
Number of subjects: 2511

Group type: COMPARATOR
Intervention: Historical NWTS-5 comparison group
Number of subjects: 2511
Study: 31449522

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for Buruli ulcer
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: High bacterial load in lesion samples
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Positive M. ulcerans culture
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Positive microscopy results
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Presence of plaques, oedematous lesions, and category II lesions
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Time to complete healing
Number of subjects: 354
Study: 31449806

Group type: EXPERIMENTAL
Intervention: Posterior repair
Number of subjects: 374

Group type: COMPARATOR
Intervention: No posterior repair
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: Overall success regardless of posterior repair
Number of subjects: 374
Study: 31450823

Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy (CANTOS Trial, NCT01327846)
Number of subjects: 0
Study: 31451367

Group type: EXPERIMENTAL
Intervention: Bevacizumab with first-line chemotherapy (capecitabine/oxaliplatin)
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Bevacizumab with first-line chemotherapy
Number of subjects: 714

Group type: EXPERIMENTAL
Intervention: Bevacizumab after disease progression
Number of subjects: 714

Group type: COMPARATOR
Intervention: Bevacizumab with capecitabine-based chemotherapy vs fluorouracil-based regimens
Number of subjects: 714
Study: 31451409

Group type: EXPERIMENTAL
Intervention: Plasma GFAP concentrations measured in patients with CT-negative and MRI-positive findings
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Plasma GFAP concentrations in patients with CT-negative and MRI-negative findings
Number of subjects: 450

Group type: COMPARATOR
Intervention: Plasma GFAP concentrations in orthopaedic trauma controls
Number of subjects: 450

Group type: COMPARATOR
Intervention: Plasma GFAP concentrations in healthy controls
Number of subjects: 450
Study: 31451445

Group type: EXPERIMENTAL
Intervention: Blinatumomab, 60 µg/m²
Number of subjects: 0
Study: 31451681

Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus
Number of subjects: 398
Study: 31451936

Group type: EXPERIMENTAL
Intervention: Maximum Back Pain (MBP)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Maximum Leg Pain (MLP)
Number of subjects: 258
Study: 31452001

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation using cryoablation (PVI-C)
Number of subjects: 2125
Study: 31452586

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (blood glucose level ≥ 169 mg/dL)
Number of subjects: 856

Group type: COMPARATOR
Intervention: Lower blood glucose level (<169 mg/dL)
Number of subjects: 856
Study: 31452899

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ECCO
Number of subjects: 70
Study: 31452902

Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus dosing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Twice-daily tacrolimus dosing
Number of subjects: 38
Study: 31452953

Group type: EXPERIMENTAL
Intervention: Allium sativum extract as an intracanal irrigant
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study: 31453076

Group type: EXPERIMENTAL
Intervention: Multi-component intervention including scripted counseling via text messages and brief motivational interviewing delivered by telephone
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group receiving a handout on the benefits of physical activity
Number of subjects: 69
Study: 31453424

Group type: EXPERIMENTAL
Intervention: High dairy product intake (HD) (≥4 servings/d) for 6 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Adequate dairy product intake (AD) (≤2 servings/d) for 6 weeks
Number of subjects: 27
Study: 31453428

Group type: EXPERIMENTAL
Intervention: Monthly mailed healthy lifestyle intervention toolkit
Number of subjects: 450
Study: 31453766

Group type: EXPERIMENTAL
Intervention: Elevated left ventricular mass quantified by MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary artery calcium (CAC) score
Number of subjects: 0
Study: 31454374

Group type: EXPERIMENTAL
Intervention: Ebola virus fluorescence reduction neutralization assay (FRNA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Filovirus Animal Non-clinical Group (FANG) ELISA
Number of subjects: 0
Study: 31454510

Group type: EXPERIMENTAL
Intervention: Estimated fetal weight percentage difference
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Birthweight discordance ≥18%
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Estimated fetal weight percent difference
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Percentage of dichorionic pregnancies exceeding a fixed discordance cut point
Number of subjects: 140
Study: 31455225

Group type: EXPERIMENTAL
Intervention: Individualized Tai-Chi (iTC) training for 8 weeks
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Traditional Tai-Chi (tTC) training for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 50
Study: 31455358

Group type: EXPERIMENTAL
Intervention: Wearable device for gait rehabilitation (30 min walking sessions, 3 times per week for 4 weeks)
Number of subjects: 6
Study: 31455612

Group type: EXPERIMENTAL
Intervention: Model 1 (all predictors included)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Model 2 (QFT excluded)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Model 3 (ultrasonography excluded)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Model 4 (QFT and ultrasonography excluded)
Number of subjects: 438
Study: 31455681

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (0.3 or 1.0 mg/kg) and Nivolumab (3.0 mg/kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Mogamulizumab and Nivolumab
Number of subjects: 96
Study: 31455684

Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound assessment before starting NIV (T0), after the first hour (T1), and after the second hour (T2).
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Diaphragmatic ultrasound assessment at T0, T1, and T2.
Number of subjects: 22
Study: 31455696

Group type: EXPERIMENTAL
Intervention: Chinese version of TRACK
Number of subjects: 321
Study: 31455712

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 1200 mg of elemental calcium during pregnancy and lactation
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Early life exposure to lead
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Dietary factors, genetic polymorphisms, timing of exposure
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Other toxicants (phthalates, bisphenol A, mercury, manganese, cadmium, organophosphates, fluoride)
Number of subjects: 1643
Study: 31455743

Group type: EXPERIMENTAL
Intervention: Multiecho fMRI denoising
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31455851

Group type: EXPERIMENTAL
Intervention: Obinutuzumab plus fludarabine and cyclophosphamide (G-FC)
Number of subjects: 140
Study: 31456070

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PRO) using the Neuropathic Pain Scale (NPS) and Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity (FACT/GOG-Ntx)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) measuring tactile and vibration detection thresholds
Number of subjects: 49
Study: 31456142

Group type: EXPERIMENTAL
Intervention: ONC201 (administered orally once every week)
Number of subjects: 18
Study: 31456261

Group type: EXPERIMENTAL
Intervention: Plerixafor 0.32 mg/kg and bortezomib 1.3 mg/m²
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Plerixafor in combination with bortezomib
Number of subjects: 58
Study: 31456363

Group type: EXPERIMENTAL
Intervention: Deep Learning (DL) algorithm
Number of subjects: 412030

Group type: COMPARATOR
Intervention: Cox hazard regression
Number of subjects: 412030
Study: 31456431

Group type: EXPERIMENTAL
Intervention: ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31456995

Group type: EXPERIMENTAL
Intervention: Resistance training combined with stretching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stretching alone
Number of subjects: 0
Study: 31461380

Group type: EXPERIMENTAL
Intervention: Neoadjuvant single-agent oral talazoparib once per day for 6 months
Number of subjects: 20
Study: 31462235

Group type: EXPERIMENTAL
Intervention: SGRQ-I
Number of subjects: 150

Group type: COMPARATOR
Intervention: SGRQ
Number of subjects: 150

Group type: COMPARATOR
Intervention: King's Brief Interstitial Lung Disease questionnaire (K-BILD)
Number of subjects: 150

Group type: COMPARATOR
Intervention: University of California, San Diego Shortness of Breath Questionnaire (SOBQ)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Short Form-36 (SF-36)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Global Rating of Change Scales (GRCS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: 6-min walk test (6MWT)
Number of subjects: 150
Study: 31462437

Group type: EXPERIMENTAL
Intervention: Detection of human enterovirus (HEV) in plasma
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Detection of human parechovirus (HPeV) in plasma
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Detection of adenovirus (AdV) in plasma
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Detection of human herpesvirus type 6 (HHV-6) in plasma
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Viraemia in children with FWS
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Antibiotic use in patients with viraemia
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Risk of serious bacterial infection (SBI) among patients with viraemia
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control cohort testing for viruses in blood
Number of subjects: 135
Study: 31462933

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 38
Study: 31463079

Group type: EXPERIMENTAL
Intervention: GAPcare intervention (multidisciplinary fall prevention protocol)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 120
Study: 31463078

Group type: EXPERIMENTAL
Intervention: Heavy-slow resistance training (HSR) combined with ultrasound-guided corticosteroid injection
Number of subjects: 20
Study: 31463362

Group type: EXPERIMENTAL
Intervention: Higher injection pressure (550 pound/inch)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Lower injection pressure
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Higher injection pressure
Number of subjects: 100
Study: 31463874

Group type: EXPERIMENTAL
Intervention: FACS-sorting of spermatozoa with fragmented DNA
Number of subjects: 104

Group type: COMPARATOR
Intervention: Swim-up
Number of subjects: 104
Study: 31464190

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM) program for pregnant women at risk of PIH
Number of subjects: 108
Study: 31464589

Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH), an electronic self-management support system
Number of subjects: 446
Study: 31464712

Group type: EXPERIMENTAL
Intervention: Postoperative delirium (POD) diagnosed using the Confusion Assessment Method for the ICU on postoperative day 1 or day 3.
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Independent risk factors for POD include age, nature of intracranial lesion, frontal approach craniotomy, duration of surgery, presence of an episode of low pulse oxygenation at ICU admission, presence of inadequate emergence and emergence delirium, postoperative pain and presence of immobilising events.
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: POD association with adverse outcomes and high costs.
Number of subjects: 800
Study: 31464752

Group type: EXPERIMENTAL
Intervention: Unilateral chronic neck pain patients
Number of subjects: 49
Study: 31464769

Group type: EXPERIMENTAL
Intervention: Diaries
Number of subjects: 5165

Group type: EXPERIMENTAL
Intervention: Exercise programs
Number of subjects: 5165
Study: 31464935

Group type: EXPERIMENTAL
Intervention: Barricaid annular closure device
Number of subjects: 75

Group type: COMPARATOR
Intervention: Historical controls from a previous European randomized trial
Number of subjects: 75
Study: 31465427

Group type: EXPERIMENTAL
Intervention: Fatty liver index (FLI)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Changes in FLI
Number of subjects: 389

Group type: COMPARATOR
Intervention: Full model including diabetes risk score, FPG, HbA1C and FLI
Number of subjects: 389

Group type: COMPARATOR
Intervention: HOMA-IR
Number of subjects: 389
Study: 31466481

Group type: EXPERIMENTAL
Intervention: Thermal ablation
Number of subjects: 0
Study: 31466616

Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) after bioprosthetic AVR
Number of subjects: 4832

Group type: EXPERIMENTAL
Intervention: Anticoagulation (AC) after surgical AVR (SAVR)
Number of subjects: 4832

Group type: COMPARATOR
Intervention: No anticoagulation (Control group) after bioprosthetic AVR
Number of subjects: 4832
Study: 31467059

Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 inhibitor)
Number of subjects: 0
Study: 31467127

Group type: EXPERIMENTAL
Intervention: Genomic alterations
Number of subjects: 0
Study: 31467520

Group type: COMPARATOR
Intervention: fALFF analysis in broadband frequency band (~0.01-0.08 Hz)
Number of subjects: 63

Group type: COMPARATOR
Intervention: fALFF analysis in slow-5 frequency band (~0.01-0.027 Hz)
Number of subjects: 63

Group type: COMPARATOR
Intervention: fALFF analysis in slow-4 frequency band (0.027-0.07 Hz)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Overall fALFF analysis across three frequency bands
Number of subjects: 63
Study: 31467583

Group type: EXPERIMENTAL
Intervention: Carbohydrate-restricted (CR) diet
Number of subjects: 0
Study: 31467699

Group type: EXPERIMENTAL
Intervention: 1200 mg of protein hydrolysate from Coldwater Shrimp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31468255

Group type: EXPERIMENTAL
Intervention: Preattached multichannel intraluminal impedance monitoring combined with pH-metry
Number of subjects: 0
Study: 31468637

Group type: EXPERIMENTAL
Intervention: Second-line glucose-lowering therapy
Number of subjects: 15992

Group type: EXPERIMENTAL
Intervention: Factors associated with poor glycaemic control (HbA1c >8.0%)
Number of subjects: 15992
Study: 31469058

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin/doxorubicin administered during standard laparoscopy
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Pressurized intraperitoneal aerosol chemotherapy (PIPAC)
Number of subjects: 13
Study: 31470902

Group type: EXPERIMENTAL
Intervention: Obinutuzumab (Gazyvaro) combined with low-dose radiotherapy (LDRT)
Number of subjects: 93
Study: 31471185

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Baseline DTI metrics
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Effect sizes
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Temporal changes in DTI metrics
Number of subjects: 200
Study: 31471313

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Regorafenib 120 mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Combination of sunitinib and regorafenib
Number of subjects: 14
Study: 31471312

Group type: EXPERIMENTAL
Intervention: GSK2816126 (EZH2 inhibitor) at doses ranging from 50 to 3,000 mg twice weekly, given 3-weeks-on/1-week-off in 28-day cycles
Number of subjects: 41
Study: 31471324

Group type: EXPERIMENTAL
Intervention: Low-dose interleukin-2 (IL-2) therapy
Number of subjects: 0
Study: 31471376

Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine (AZA) 300 mg daily on days 1 to 14 and romidepsin (ROMI) 14 mg/m2 on days 8, 15, and 22 on a 35-day cycle
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Oral 5-azacytidine (AZA) 100 mg daily on days 1 to 14 to 300 mg daily on days 1 to 21 and romidepsin (ROMI) 10 mg/m2 on days 8 and 15 to 14 mg/m2 on days 8, 15, and 22
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-T-cell lymphoma patients
Number of subjects: 31
Study: 31471433

Group type: EXPERIMENTAL
Intervention: Early point-of-care focused echocardiography (EPOCE) performed during the automated external defibrillator's analysis period.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EPOCE asystole
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: EPOCE technique
Number of subjects: 8
Study: 31471442

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 37614

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 37614
Study: 31471961

Group type: EXPERIMENTAL
Intervention: FLOODLIGHT test battery (active tests and passive monitoring)
Number of subjects: 76